相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
Yi-Zhou Jiang et al.
CELL RESEARCH (2021)
A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer
Aurelia Noske et al.
HISTOPATHOLOGY (2021)
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients
Jieqiong Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Leisha A. Emens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity
Eun-Sook Kim et al.
ONCOGENE (2021)
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
L. A. Emens et al.
ANNALS OF ONCOLOGY (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
J. Cortes et al.
ANNALS OF ONCOLOGY (2021)
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
P. Schmid et al.
ANNALS OF ONCOLOGY (2021)
Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma
Michelle R. Downes et al.
HISTOPATHOLOGY (2020)
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
Nicola L. Lawson et al.
MODERN PATHOLOGY (2020)
Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
Emina Torlakovic et al.
MODERN PATHOLOGY (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
R. Barroso-Sousa et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer
Caroline Bergenfelz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Romualdo Barroso-Sousa et al.
CLINICAL CANCER RESEARCH (2020)
Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
Francesca Giunchi et al.
CURRENT DRUG TARGETS (2020)
Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC
Joe Yeong et al.
JOURNAL OF CLINICAL PATHOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Overexpression of IL-8 promotes cell migration via PI3K-Akt signaling pathway and EMT in triple-negative breast cancer
Fang Deng et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T. Karn et al.
ANNALS OF ONCOLOGY (2020)
Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy
Marie K. Malone et al.
CANCER BIOLOGY & THERAPY (2020)
Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors
Lara Gibellini et al.
FRONTIERS IN IMMUNOLOGY (2020)
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Jieqiong Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Kurt A. Schalper et al.
NATURE MEDICINE (2020)
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
V. Prasad et al.
ANNALS OF ONCOLOGY (2020)
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Lynette Sholl et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study
Parisa Lotfinejad et al.
DIAGNOSTICS (2020)
RNA sequencing: new technologies and applications in cancer research
Mingye Hong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
H. Iwata et al.
ANNALS OF ONCOLOGY (2020)
Understanding PD-L1 Testing in Breast Cancer: A Practical Approach
Ramona Erber et al.
BREAST CARE (2020)
Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)
Sherene Loi et al.
CANCER RESEARCH (2020)
Cytokines in the Treatment of Cancer
Kevin C. Conlon et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
The neoepitope landscape of breast cancer: implications for immunotherapy
Pooja Narang et al.
BMC CANCER (2019)
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Yi-Zhou Jiang et al.
CANCER CELL (2019)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro et al.
CANCER DISCOVERY (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Predictive potential and need for standardization of PD-L1 immunohistochemistry
Spasenija Savic Prince et al.
VIRCHOWS ARCHIV (2019)
Influence of Interleukin-8 and Neutrophil Extracellular Trap (NET) Formation in the Tumor Microenvironment: Is There a Pathogenic Role?
Manuela Gonzalez-Aparicio et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
Current Landscape of Immunotherapy in Breast Cancer: A Review
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis
Wenfa Huang et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
Lynn G. Feun et al.
CANCER (2019)
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
Heng-Huan Lee et al.
CANCER CELL (2019)
Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer
Yuan-sheng Zang et al.
CANCER MEDICINE (2019)
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Rui-Mei Feng et al.
CANCER COMMUNICATIONS (2019)
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
Lindsay Angus et al.
NATURE GENETICS (2019)
Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC)
Elizabeth F Blackley et al.
BREAST (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer
Hye Ryun Kim et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1
Jamaal L. James et al.
CURRENT BREAST CANCER REPORTS (2019)
IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab plus nab-paclitaxel in patients with treatment-naive, locally advanced or metastatic triple-negative breast cancer
L. A. Emens et al.
CANCER RESEARCH (2019)
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells
Varun Sasidharan Nair et al.
IMMUNOLOGY AND CELL BIOLOGY (2018)
Predicting the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: Usefulness of breast MRI computer-aided detection and diagnosis
You Jin Ku et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2018)
Cytokines in Cancer Immunotherapy
Thomas A. Waldmann
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Y. Bareche et al.
ANNALS OF ONCOLOGY (2018)
Phase 2 study and correlative analyses of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic, triple-negative breast cancer
Daniel G. Stover et al.
CANCER RESEARCH (2018)
Chemokines: the past, the present and the future
Peng Tang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
PD-L1 in breast cancer: comparative analysis of 3 different antibodies
Tejashree Karnik et al.
HUMAN PATHOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
F. Klauschen et al.
SEMINARS IN CANCER BIOLOGY (2018)
Immunological differences between primary and metastatic breast cancer
B. Szekely et al.
ANNALS OF ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Jinfang Zhang et al.
TRENDS IN BIOCHEMICAL SCIENCES (2018)
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Colt A. Egelston et al.
NATURE COMMUNICATIONS (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
Michael T. Barrett et al.
BREAST CANCER RESEARCH (2018)
Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice
Efimia Boutsikou et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
Gerardo Botti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients
Nitin Chakravarti et al.
MELANOMA RESEARCH (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer
Kenji Gonda et al.
ONCOLOGY LETTERS (2017)
Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade
Maria Ouzounova et al.
NATURE COMMUNICATIONS (2017)
CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function
Xi Chen et al.
ONCOTARGET (2017)
Elevated T cell activation score is associated with improved survival of breast cancer
Lingeng Lu et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma
Naoya Yamazaki et al.
CANCER SCIENCE (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer
Xiaoxian Li et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2016)
Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer
Jacqueline Tsai et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Immune checkpoint blockade: Releasing the brake towards hematological malignancies
Yi Xia et al.
BLOOD REVIEWS (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-L1 expression in human cancers and its association with clinical outcomes
Xin Wang et al.
ONCOTARGETS AND THERAPY (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Yi-Rong Liu et al.
BREAST CANCER RESEARCH (2016)
The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
Justin M. David et al.
VACCINES (2016)
Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis
Haiming Yu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Christoffer Gebhardt et al.
CLINICAL CANCER RESEARCH (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients
Caroline Bergenfelz et al.
PLOS ONE (2015)
Classical pathology and mutational load of breast cancer - integration of two worlds
Jan Budczies et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data
Svasti Haricharan et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
Caroline Jochems et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
Hatem Soliman et al.
PLOS ONE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels
Anna M. Leung et al.
FRONTIERS IN ONCOLOGY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
Jinpu Yu et al.
JOURNAL OF IMMUNOLOGY (2013)
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
Yago Pico de Coana et al.
CANCER IMMUNOLOGY RESEARCH (2013)
FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis
Miki Takenaka et al.
MOLECULAR AND CLINICAL ONCOLOGY (2013)
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
F. Andre et al.
ANNALS OF ONCOLOGY (2012)
A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer
N. Steele et al.
BRITISH JOURNAL OF CANCER (2012)
Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network
Nancy U. Lin et al.
CANCER (2012)
Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
Ping Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
Samantha Solito et al.
BLOOD (2011)
Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Minu K. Srivastava et al.
CANCER RESEARCH (2010)
The terminology issue for myeloid-derived suppressor cells
Dmitry I. Gabrilovich et al.
CANCER RESEARCH (2007)
分享论文
